Fisher & Paykel Healthcare: Executive share rights lapse as conditions unmet

Fisher & Paykel Healthcare Corporation Limited announced on September 5, 2025, that 412,417 options and 130,857 performance share rights, issued on September 4, 2020, have lapsed. These lapses occurred because the conditions for vesting under the company's discretionary long-term variable remuneration plans were not met.

Specifically, 389,859 unquoted options, expiring on September 4, 2025, with an exercise price of NZD 36.54, and 123,694 unquoted performance share rights, expiring on September 4, 2025, ceased to exist. These cessations impact several key executives, including Andrew Robert Donald Somervell (vice president - products & technology), Andrew Grant Niccol (chief operating officer), Justin Peter Callahan (vice president - sales & marketing), Lewis George Gradon (chief executive officer), and Lyndal Jane York (chief financial officer). No consideration was paid by the entity for these cessations.

Following these lapses, the company's unquoted securities have been updated. The total number of quoted ordinary fully paid foreign exempt NZX securities (FPH) remains unchanged at 587,241,171.